Dr. Reddy's Laboratories (RDY) Competitors $14.35 +0.25 (+1.77%) (As of 11/19/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends RDY vs. TAK, BNTX, TEVA, BGNE, VTRS, MRNA, SMMT, GMAB, PCVX, and CTLTShould you be buying Dr. Reddy's Laboratories stock or one of its competitors? The main competitors of Dr. Reddy's Laboratories include Takeda Pharmaceutical (TAK), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Viatris (VTRS), Moderna (MRNA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Vaxcyte (PCVX), and Catalent (CTLT). These companies are all part of the "pharmaceutical products" industry. Dr. Reddy's Laboratories vs. Takeda Pharmaceutical BioNTech Teva Pharmaceutical Industries BeiGene Viatris Moderna Summit Therapeutics Genmab A/S Vaxcyte Catalent Dr. Reddy's Laboratories (NYSE:RDY) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings. Do institutionals and insiders hold more shares of RDY or TAK? 14.0% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts recommend RDY or TAK? Dr. Reddy's Laboratories presently has a consensus target price of $17.00, indicating a potential upside of 18.47%. Given Dr. Reddy's Laboratories' stronger consensus rating and higher probable upside, analysts clearly believe Dr. Reddy's Laboratories is more favorable than Takeda Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Takeda Pharmaceutical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, RDY or TAK? Dr. Reddy's Laboratories has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500. Does the media prefer RDY or TAK? In the previous week, Takeda Pharmaceutical had 3 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 6 mentions for Takeda Pharmaceutical and 3 mentions for Dr. Reddy's Laboratories. Takeda Pharmaceutical's average media sentiment score of 0.59 beat Dr. Reddy's Laboratories' score of -0.38 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Takeda Pharmaceutical 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor RDY or TAK? Dr. Reddy's Laboratories received 221 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 59.55% of users gave Dr. Reddy's Laboratories an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote. CompanyUnderperformOutperformDr. Reddy's LaboratoriesOutperform Votes32159.55% Underperform Votes21840.45% Takeda PharmaceuticalOutperform Votes10056.82% Underperform Votes7643.18% Is RDY or TAK a better dividend stock? Dr. Reddy's Laboratories pays an annual dividend of $0.08 per share and has a dividend yield of 0.6%. Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 3.5%. Dr. Reddy's Laboratories pays out 12.8% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 82.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Which has higher valuation & earnings, RDY or TAK? Takeda Pharmaceutical has higher revenue and earnings than Dr. Reddy's Laboratories. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDr. Reddy's Laboratories$3.35B3.58$668M$0.6322.92Takeda Pharmaceutical$28.20B1.54$994.06M$0.5823.48 Is RDY or TAK more profitable? Dr. Reddy's Laboratories has a net margin of 17.81% compared to Takeda Pharmaceutical's net margin of 6.49%. Dr. Reddy's Laboratories' return on equity of 18.53% beat Takeda Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Dr. Reddy's Laboratories17.81% 18.53% 13.01% Takeda Pharmaceutical 6.49%10.00%4.78% SummaryDr. Reddy's Laboratories beats Takeda Pharmaceutical on 14 of the 20 factors compared between the two stocks. Ad DarwinNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Get Dr. Reddy's Laboratories News Delivered to You Automatically Sign up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RDY vs. The Competition Export to ExcelMetricDr. Reddy's LaboratoriesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$11.98B$6.42B$5.00B$19.91BDividend Yield0.57%8.11%7.72%3.53%P/E Ratio22.925.7282.7937.63Price / Sales3.58383.001,398.1518.41Price / Cash13.9722.1633.2217.95Price / Book3.555.404.665.66Net Income$668M$152.87M$117.62M$983.90M7 Day Performance-2.78%-7.98%-2.93%-0.67%1 Month Performance-9.94%-8.75%-3.98%0.47%1 Year Performance7.28%27.98%30.32%24.55% Dr. Reddy's Laboratories Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RDYDr. Reddy's Laboratories1.3932 of 5 stars$14.35+1.8%$17.00+18.5%+7.3%$11.98B$3.35B22.9227,048TAKTakeda Pharmaceutical3.6761 of 5 stars$13.53-0.7%N/A-2.4%$43.05B$4.55T23.3349,281High Trading VolumeBNTXBioNTech3.5366 of 5 stars$101.87+2.2%N/A+7.1%$24.42B$4.13B-48.516,133Analyst ForecastAnalyst RevisionTEVATeva Pharmaceutical Industries2.7865 of 5 stars$16.50+0.4%N/A+85.6%$18.69B$16.77B-19.4137,851Gap DownBGNEBeiGene3.2215 of 5 stars$187.69-0.8%N/A+0.5%$18.28B$3.32B-22.7810,600Gap DownVTRSViatris1.3984 of 5 stars$13.00+1.3%N/A+38.1%$15.52B$15.43B-17.5738,000MRNAModerna4.6389 of 5 stars$39.51+7.2%N/A-51.2%$15.20B$5.06B-6.795,600Analyst UpgradeHigh Trading VolumeSMMTSummit Therapeutics1.9622 of 5 stars$18.98+3.7%N/A+936.3%$14.00B$700,000.00-67.78105Analyst ForecastGMABGenmab A/S4.3274 of 5 stars$20.67+0.4%N/A-37.5%$13.68B$2.39B20.072,204Positive NewsPCVXVaxcyte3.3304 of 5 stars$86.49-0.4%N/A+69.2%$10.82BN/A-18.80160High Trading VolumeCTLTCatalent3.0857 of 5 stars$58.78-0.5%N/A+47.6%$10.67B$4.42B-26.0116,900 Related Companies and Tools Related Companies Takeda Pharmaceutical Alternatives BioNTech Alternatives Teva Pharmaceutical Industries Alternatives BeiGene Alternatives Viatris Alternatives Moderna Alternatives Summit Therapeutics Alternatives Genmab A/S Alternatives Vaxcyte Alternatives Catalent Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:RDY) was last updated on 11/20/2024 by MarketBeat.com Staff From Our PartnersTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredTrump’s EPIC Stock Market RallyPutting HUGE gain chances in the hands of hardworking, patriotic Americans like YOU. In fact, according to ...Paradigm Press | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dr. Reddy's Laboratories Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Dr. Reddy's Laboratories With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
